Clinical Trial Update: Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics [Phase 1]

View source ↗

Summary

This ClinicalTrials.gov update outlines a Phase 1 pharmacokinetic comparison between HLX05 and Erbitux (cetuximab) in healthy Chinese male volunteers, focusing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ERBITUX (cetuximab)
• HLX05 (cetuximab)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Cancer, mCRC | Phase 1 | Status: ACTIVE_NOT_RECRUITING